RFA-DA-25-052: Tools for decentralized clinical trials for substance use disorder (R43/R44 Clinical Trials Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2023.
National Institutes of Health offered grants of up to $295,924 to small businesses. Applications closed on March 14, 2024.
From the official notice on Grants.gov, last changed October 25, 2023. Checked November 7, 2026.
- Award ceiling$295,924
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR43 / R44
- Clinical trialsOptional
- Funded byNIDA
- Median yearly award$305,372
- Typical project length1 year
- R43, Small Business Innovation Research (SBIR) Phase I. A small business tests the feasibility of a technology or product. Other open R43 notices.
- R44, Small Business Innovation Research (SBIR) Phase II. Full research and development of an SBIR project after Phase I (or both phases at once, called Fast Track). Other open R44 notices.
Projects funded under RFA-DA-25-052 were run by National Institute on Drug Abuse (NIDA, 2 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-DA-25-052 in the NIH Guide.
Key dates
| Posted | October 25, 2023 |
|---|---|
| Deadline | March 14, 2024 |
| Archived by Grants.gov | April 19, 2024 |
Who can apply
This opportunity was open to small businesses.
- Small businesses
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $305,372; it allows up to $295,924 per award.
- Most of the program's money (70% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
There are gaps that prevent the utilization of decentralized clinical trials (DCT) in substance use area. The existing sensors for physiological measurement are rarely used and may need further validation. There are no wearable or home-use detection devices on the market capable to measure substances of interest (e.g., methadone, buprenorphine, their metabolites, as well as the spectrum of illicit drugs). The devices in development are not intended for diagnostics or treatment. Most of the devices are intended for laboratory use. Most of the devices do not have standard software interface through which the devices can transmit the data to the study center.
Funded under RFA-DA-25-052 so far
NIH funded 2 projects under RFA-DA-25-052 in fiscal 2025, at 2 institutions. The median yearly award was $305,372.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Development of Validation of a Novel Software Platform for Decentralized Clinical Trial in Substance Use Disorder Incorporating Large Language Models | Carina Medical, LLC | 2025 | $304,215 |
| Development of a Medication Adherence and Monitoring System Supporting Decentralized Clinical Trials for Substance Use Disorder | Addinex Technologies, Inc. | 2025 | $306,528 |
Who has won Drug Use and Addiction Research Programs grants before
From fiscal 2021 to 2025, Drug Use and Addiction Research Programs (93.279) awarded $7.3 billion across 5,071 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Yale Univ | Connecticut | 150 | $305 million |
| The Johns Hopkins University | Maryland | 156 | $262 million |
| University of California, San Diego | California | 120 | $242 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 100 | $182 million |
| New York University | New York | 62 | $173 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-DA-25-052 still open?
No. It closed on March 14, 2024.
Who can apply for Tools for decentralized clinical trials for substance use disorder (R43/R44 Clinical Trials Optional)?
National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Tools for decentralized clinical trials for substance use disorder (R43/R44 Clinical Trials Optional)?
Closed March 14, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $295,924 each.
Who has been funded under RFA-DA-25-052?
NIH RePORTER lists 2 projects funded under RFA-DA-25-052 in fiscal 2025, at 2 institutions. The most were at Carina Medical, LLC, Addinex Technologies, Inc.
Who has won Drug Use and Addiction Research Programs grants before?
The largest recipients over five fiscal years were Yale Univ, The Johns Hopkins University, University of California, San Diego. The program made 5,071 awards worth $7.3 billion in that time.
Similar open grants
- Small Business Transition Grant for New Entrepreneurs (Parent R43/R44 Clinical Trial Optional)
- NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- Successor-in-Interest (Type 6 Parent Clinical Trial Optional)
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)